Carolyn Grande

Management of Common Adverse Events in Patients Treated With Sorafenib: Nurse and Pharmacist Perspective

Christine M. Walko, Carolyn Grande · Seminars in Oncology · 2014 · 39 citations · Full text

Pharmacotherapy, Pharmacist Perspective, Adverse Drug Reaction +17

First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group

R. Arranz, Ana García‐Noblejas, Carolyn Grande et al. · Haematologica · 2013 · 29 citations · Full text

A phase II study of everolimus (E) and sorafenib (S) in patients (PTS) with metastatic differentiated thyroid cancer who have progressed on sorafenib alone.

Marcia S. Brose, Andrea B. Troxel, Mark Yarchoan et al. · Journal of Clinical Oncology · 2015 · 21 citations

Medicine, Thyroid Disease, Pharmacology +15

A phase II trial of cabozantinib (CABO) for the treatment of radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC) in the first-line setting.

Marcia S. Brose, Sangeeta Shenoy, Nikhil Bhat et al. · Journal of Clinical Oncology · 2018 · 21 citations

Rai-refractory Dtc, Pharmacotherapy, Endocrine Oncology +19

Potential of Biosimilars to Increase Access to Biologics: Considerations for Advanced Practice Providers in Oncology

Sara Tinsley, Carolyn Grande, Karin Olson et al. · Journal of the Advanced Practitioner in Oncology · 2018 · 17 citations · Full text

Preclinical Therapeutics, Cancer Management, Surgery +19